Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more
Cytokinetics regains European rights from Servier to heart failure program
Cytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier. The deal termination comes a month after Amgen Inc. (NASDAQ:AMGN) returned its rights to the cardiac myosin activator. In October, omecamtiv mecarbil led to a statistically significant reduction in time to cardiovascular death or first heart failure event in the Phase III GALACTIC-HF trial, but missed on the secondary endpoint of reduction in time to CV death alone. Cytokinetics plans to meet with regulatory bodies next year to assess a path forward.
Boehringer, Epizyme terminate epigenetic deal
Boehringer Ingelheim GmbH and Epizyme Inc. (NASDAQ:EPZYM) terminated a 2018 collaboration to develop small molecule inhibitors of two epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. ...